A Riverside County mother is hoping to get some help from the public after her 10-year-old son has been diagnosed with a rare ...
The FDA granted accelerated approval to tovorafenib (Ojemda) for children 6 months and up with relapsed or refractory ...
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Glioma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Glioma - Pipeline Insight, 2024" report ...
Day One Marks Milestone in Pediatric Cancer as Tovorafenib Approved in BRAF-Mutated Low-Grade Glioma
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The Food and Drug Administration (FDA) has granted accelerated approval to Ojemda ™ (tovorafenib) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) ...
The FDA granted accelerated approval to tovorafenib (Ojemda) to treat patients with relapsed or refractory BRAF -altered ...
Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...
The combination of Novartis’ Finlee (dabrafenib) and Spexotras (trametinib) is now recommended by NICE for paediatric ...
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the ...
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback